For the 200-mg dose (in either form) or the 100-mg syringe, remove it from the refrigerator at least 30 minutes before your injection. After you bring a dose of Dupixent to room temperature ...

Dupixent (dupilumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as atopic dermatitis (a type of eczema). Dupixent comes in a prefilled syringe or prefilled ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Regeneron announced Friday that the company won Food and Drug Administration approval for Dupixent in chronic obstructive ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for certain inflammatory conditions. Dupixent has interactions with some other drugs. Examples include certain ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with eosinophilic esophagitis, expanding its market potential ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...